Aytu BioPharma, Inc. (AYTU)
AYTUNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.79
-0.0200 (-1.10%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $19.45m
- P/E
- –
- EPS, last 4 quarters
- $-1.71
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.75 to $3.07
- Average volume
- 34.7k
- Previous close
- $1.81
Analysts
3 coveringHold3 buy, 0 hold, 0 sell
Targets a year out average $9.67, +440.2% from here
Earnings
next estimate $-0.1000Next report Nov 12, 2026
Sep 2025
-33.3%
Dec 2025
-303.9%
Mar 2026
-71.0%
Jun 2026
+77.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $13.89m | $15.16m | $12.41m | $16.11m |
| Gross profit | $9.19m | $9.62m | $7.60m | $10.41m |
| Operating income | -$1.50m | -$1.97m | -$4.06m | -$777.0k |
| Net income | $1.97m | -$10.58m | -$5.62m | -$15.0k |
Last four quarters: revenue $57.57m, margin -24.8%, free cash flow –
News
8 latest- CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue EstimatesZacks · 4 days ago
- Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?Zacks · Oct 7, 2026
- Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue EstimatesZacks · Sep 22, 2026
- HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue EstimatesZacks · Sep 14, 2026
- New Strong Sell Stocks for July 20thZacks · Jul 20, 2026
- Aytu (AYTU) Q3 2026 Earnings TranscriptThe Motley Fool · May 13, 2026
- Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue EstimatesZacks · May 13, 2026
- Immatics (IMTX) Reports Q1 Loss, Lags Revenue EstimatesZacks · May 12, 2026
The company
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA® (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- aytubio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.